Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria | Annals of Surgical Oncology
Cancers | Free Full-Text | Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study
JCM | Free Full-Text | C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data | PLOS ONE
Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis
Survival and Prognostic Factors in Pancreatic and Ampullary Cancer | Anticancer Research
Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy
Frontiers | Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection
JCM | Free Full-Text | Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
Frontiers | Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival
Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis
The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data | Scientific Reports
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial - The Lancet Oncology
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study | BMC Cancer | Full Text
Overall survival in patients with pancreatic cancer according to the... | Download Scientific Diagram
Survival analysis of PDAC patients by Kaplan-Meier plots and log-rank... | Download Scientific Diagram
![PDF] Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8faa1d8f68b65770edd2aeca36796df9f4345753/6-Figure2-1.png "PDF] Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. | Semantic Scholar")
PDF] Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. | Semantic Scholar
Does perioperative chemotherapy improve outcomes in PDAC?
Cancers | Free Full-Text | Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer - Guenther - 2022 - International Journal of Cancer - Wiley Online Library
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | NEJM
Pancreatic adenocarcinomas with mature blood vessels have better overall survival | Scientific Reports
Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
